

BC

VITRONECTIN RECEPTOR ANTAGONISTS**Publication number:** JP10504808T**Publication date:** 1998-05-12**Inventor:****Applicant:****Classification:****- International:**

A61K31/415; A61K31/4184; A61K31/44; A61K31/4427; A61K31/443; A61K31/445; A61K31/454; A61K31/47; A61K31/495; A61K31/496; A61K31/55; A61K31/551; A61P9/10; A61P19/10; A61P29/00; A61P35/00; A61P43/00; C07D223/16; C07D233/56; C07D233/64; C07D235/14; C07D235/20; C07D243/14; C07D401/06; C07D401/12; C07D401/14; C07D403/06; C07D403/12; C07D403/14; C07D405/12; C07D405/14; C07D413/12; C07D417/12; C07D471/04; C07D491/04; C07D491/056; A61K31/415; A61K31/4164; A61K31/44; A61K31/4427; A61K31/445; A61K31/4523; A61K31/47; A61K31/495; A61K31/496; A61K31/55; A61K31/551; A61P9/00; A61P19/00; A61P29/00; A61P35/00; A61P43/00; C07D223/00; C07D233/00; C07D235/00; C07D243/00; C07D401/00; C07D403/00; C07D405/00; C07D413/00; C07D417/00; C07D471/00; C07D491/00; (IPC1-7): C07D243/14; C07D235/14; A61K31/415; A61K31/44; A61K31/445; A61K31/47; A61K31/495; A61K31/55; C07D235/20; C07D401/12; C07D401/14; C07D403/06; C07D403/12; C07D403/14; C07D405/12; C07D405/14; C07D413/12; C07D417/12; C07D471/04

- European:

C07D223/16C; C07D235/14; C07D243/14; C07D401/06; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D413/12; C07D417/12; C07D471/04; C07D491/04

Application number: JP19950503462T 19950629**Priority number(s):** WO1995US08306 19950629; US19940267695 19940629; US19950428933 19950425**Also published as:**

WO9600730 (A1)



EP0767792 (A1)



EP0767792 (A0)



CA2193966 (A1)



BR9508178 (A)

[more >>](#)[Report a data error here](#)

Abstract not available for JP10504808T

Abstract of corresponding document: **WO9600730**

Compounds are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. These compounds comprise a fibrinogen receptor antagonist template linked to a heterocyclic moiety.

Data supplied from the **esp@cenet** database - Worldwide